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The anthracycline drug daunorubicin (DNR) is, together with cytarabine, the most commonly 
used chemotherapeutic agents against acute myeloid leukemia (AML) and has been so for the 
last 40 years. AML is a disease with low survival rate, and is most common among the elderly 
with a median age of diagnosis at around 70 years. The current treatment method is impaired 
by low tolerance and severe dose-related side-effects, including myelosuppression. Improved 
treatment methods, especially for frailer patients, are needed.  
Previous studies has shown that the combination of a protein synthesis inhibitor 
(cycloheximide or emetine (EME)) with DNR is shown to act synergistic in inducing AML 
cell death. Furthermore, by introducing EME 30 minutes after DNR, the anti-AML effect was 
further enhanced. By incorporating EME and DNR in a dual-compound liposome, equal 
pharmacokinetics of the compounds and simultaneous release at the target are ensured. 
Incorporating anthracyclines in liposomes has shown to lower side-effects of the drugs, thus 
improving the current treatment method.  
An EME analog, FG1181, was developed in order to ensure sequential drug delivery to cells. 
FG1181 is expected to be metabolized into EME after 20-30 minutes, thus ensuring the 
advantageous delayed protein synthesis inhibition after exposure to DNR. This thesis presents 
the documentation of FG1181 with respect to chemical properties, cytotoxicity, and also the 
development of a method for producing liposomes loaded with both FG1181 and DNR. We 
demonstrate that FG1181 is less potent towards AML cells compared to EME, and has delayed 
toxic effect. Furthermore, the compound can be loaded into liposomes with a modified acid 
precipitation method, using incubation at low temperatures to prevent hydrolysis of FG1181 
into EME during production of liposomes. 
Finally, we found that liposomes loaded with FG1181 and DNR had higher anti-AML activity 
than liposomes loaded with EME and DNR, suggesting that the advantageous effect of 
sequential drug delivery is obtained by the prodrug concept. In conclusion, small molecules, 
here loaded into liposomes, are promising in the field of cancer therapy and can be expected to 






1.1.  Acute myeloid leukemia 
Leukemia is a group of cancerous diseases defined by chromosomal translocation or mutation 
in the hematopoietic stem cells (HSCs) lineage (1, 2). During normal hematopoiesis,                                                                                                                                    
HSCs mature into different blood cells in the lymphoid and myeloid cell lineage, as illustrated 
in Figure 1.1 (3, 4). However, the leukemia stem cells (LSCs) do not lead to proliferation of 
healthy blood cells like their non-mutated counterparts HSCs (5). LSCs have terminated 
differentiation, meaning that there will be an accumulation of immature precursor cells, termed 
blasts, in the bone marrow and peripheral blood, or other hematopoietic or lymphoid organs 
(6).  
 
Figure 1.1 - The process of hematopoiesis. The figure illustrates the different lineages in hematopoiesis for 
HSCs. The red figure farthest to the left represents the common myeloid progenitor. Mutations in this progenitor 
could lead to myeloid leukemia, while mutations in the green lymphoid progenitor can lead to lymphoid cancers. 




Leukemia is classified based on the degree of blast proliferation and morphological 
differentiation, and on the clinical course of the patients (5, 8). Acute leukemia is mutations in 
the most immature precursor cells, characterized by a high degree of proliferation, lack of 
morphological differentiation, and rapid disease progress (4, 8). Acute leukemia develops 
rapidly during weeks or months, and requires immediate medical treatment (9). Chronic 
leukemia cells, on the other hand, derive from more mature blast cells. It is characterized by a 
low proliferation rate, slower clinical development, and accumulation of nonfunctional cells 
resisting apoptosis (1, 8).  
Acute leukemia leads to hematopoietic insufficiency because of the rapidly multiplying blasts 
consuming the nutrients and space in the blood marrow intended for normal hematopoiesis (8, 
10). This results in deficient production of erythrocytes, leukocytes and thrombocytes, causing 
insufficient oxygen transport, leading to perceptible symptoms like fatigue, shortness of breath, 
anemia and bone pain (8, 11). Other symptoms include cold sores or gingivitis, frequent 
infections, weight loss and fever of unknown origin, caused by the immune system being 
impaired by a subnormal level of leukocytes (11). An increase in hematomas and bleeding is 
caused by an insufficient number of thrombocytes.  
Half a century ago, acute leukemia was considered incurable and palliative care was the only 
option (3). Today there is multiple treatment methods depending on subclassification of the 
disease. Acute lymphatic leukemia (ALL) entails mutations in lymphoblasts line illustrated as 
green in Figure 1.1 and is the most common type of leukemia in children aged 0-19 (12). This 
thesis will focus on acute myeloid leukemia (AML), a condition with mutations in the most 
immature myeloblast line illustrated as red in Figure 1.1 (4). AML is the second most common 
type of leukemia for adults, and the most common acute leukemia for patients aged 20 years 
and over (4).  
Every year around 200 patients are diagnosed with acute leukemia in Norway, where 160 of 
these are AML (11). In the United States of America (USA), it was estimated that around 
19,520 new patients would be diagnosed in 2018, of which 10,670 would die as a result of the 
disease (12). Figure 1.2 shows the age distribution and incidence rate per 100,000 for diagnosis 
per year in the United Kingdom (UK), which is comparable to Norway (13). The figure shows 
that the incidence rate per 100,000 is higher for men compared to women. In the US, the median 
age for patients diagnosed with AML is 67 years and 75% of newly diagnosed patients are 
older than 60 years (4, 14, 15). As life expectancies in Norway have increased with 5 years for 
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women and 8 years for men in the last 30 years, it becomes apparent that an increase in AML 
incidences can be expected (16).  
 
 
Figure 1.2 – Age distribution of AML diagnosis. The figure indicates time of AML diagnosis separated by age 
and gender. The vertical columns indicate the number of diagnosis per year relative to the left y-axis. The 
incidence rate per 100,000 for age and gender is illustrated as continuous lines relative to the y-axis on the right 
side. The numbers are based on data for 2013-2015. Figure adapted from Cancer Research UK (13).  
 
The American Cancer Society assume a 24% overall survival rate of five years for adults 
diagnosed with AML (12). The European Union estimates a 5-year survival rate of 19%, with 
3-8% for patients aged ≥ 60 years, which is significantly less than for other cancer types (14, 
15, 17). Figure 1.3 shows disease and age dependent survival prognosis based on the National 
Cancer Research Institute of UK and the Swedish Acute Leukemia Registry (18, 19). The 
patients’ diseases are classified as favorable, intermediate or adverse based on factors like 
cytogenetics and blast differentiation status (20, 21). The graphs clearly indicate the need for 
improved treatment methods, especially for the patients of higher age and in the adverse group. 
Patients not receiving treatment usually die within weeks or months from sequelae infection or 




Figure 1.3 – Survival prognosis of patients with AML based on age and disease characteristics. A, Overall 
survival according to age for AML patients. The data was collected from the Swedish database of diagnosis 
between 1997 and 2006, with follow up in 2008. Note the low survival rate for patients aged 65 years and older. 
Figure taken from Juliusson, Lazarevic (18). B, Survival rate based on disease characterized as favorable, 
intermediate or adverse for patients aged 16-59 in the UK. De novo is new mutation AML while therapy related 
acute myeloid leukemia (t-AML) showed in the scheme is AML caused by previous treatment with chemotherapy 
or radiation therapy. Figure adapted from Grimwade and Hills (24) and taken from Rowe and Tallman (19). 
 
The recommended treatment will be partly based upon which subgroup or genetic variation of 
the disease the patient is diagnosed with, according to classifications defined by the French-
American-British (FAB) or the World Health Organization (WHO) (25, 26). An example of 
one of the eight subgroups defined by FAB is an AML classified as AML FAB M5a, 
represented in this thesis by the cell line MOLM13 (22). MOLM13 was collected from a human 
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20-year-old male diagnosed with this specific subtype of AML. It has been shown that the 
patient’s age, comorbidity and cytogenetic and molecular abnormalities and thereby subgroup 
of disease should be considered when deciding treatment, as these factors will have a 
significant  impact on the patient’s recovery expectancies (27).   
The primary treatment recommended by the Norwegian Directorate of Health and most 
commonly used for patients up to 65 years is the “7+3”-regimen developed in 1973 (14). The 
regimen is a combination of infusions of the anthracycline drug daunorubicin (DNR) for 3 days 
and continuous infusions of the nucleoside metabolic inhibitor cytarabine (ara-C) for 7 days 
(9). In some cases, idarubicin (IDA) is used as an alternative to DNR (11). Because of the 
severity of the disease and the rapidness of its development, the cytostatic treatment should be 
started no longer than five days after diagnosis (11). For patients over 60 years of age, the 
dosages administered are reduced or palliative care considered if the patient has a poor general 
condition. This is to minimize drug-related side-effects, including myelosuppression (28). In 
addition, elderly patients have a high risk of developing complications and comorbidities (29). 
Thus, there is a dire need for treatments which is tolerable also for the weakest patients, and 
which also are more efficient to prevent relapse.  
An important factor when discussing AML treatment is the frequent relapses followed by 
treatment resistance. The presence of LSCs surviving the cytostatic treatment eventually leads 
to relapse and drug resistance for a high number of AML patients (6, 30). Many patients 
responding well to induction therapy, reaching complete remission, relapses within three years 
with poor prognosis and few treatment options (10).  
The development of alternative treatment options include stem cell transplantations and 
advanced drug delivery systems (DDSs) (14). Stem cell transplantation is a high-risk procedure 
that can be offered for patients with high relapse risk to avoid resistance (31). The risks of the 
operation and graft-versus-host disease associated with the procedure restricts usage to patients 
under 55-60 years in Norway (32). Liposomal DNR have been tested in the form of Daunoxome 
to minimize side-effects, but was discontinued as treatment of AML (33). Vyxeos (CPX-351) 
is a liposomal formulation containing DNR and ara-C in a 1:5 ratio approved for t-AML and 
AML with myelodysplasia-related changes (AML-MRC) (34). The drug was approved in the 
USA and the European Union in 2018, and shows a significantly higher overall survival rate 
than the “7+3”-regime, with less side-effects (17, 34). The liposomal formulation is given 
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intravenously three times over five days, and is currently undergoing clinical trials for use 
against other AML subtypes in the USA (35).  
 
1.2. Nanosized drug delivery systems 
In the last decades, nanoparticles have been introduced as possible DDSs to overcome 
difficulties in medical treatment. According to the European commission’s definition of 
nanoparticles, 50% of the total particle population should be in the size distribution of 1-100 
nm, but in nanomedicine particles up to 1000 nm in at least one dimension are commonly 
accepted as nanoparticles (36, 37). Nanoparticles are used in medicine for oral, local, topical 
and systemic (intravenous) use in the field of anesthetics, iron-replacement therapy, ultrasound 
enhancement, vaccines, fungal treatment and cancer therapy (28, 38). Figure 1.4 illustrates a 
selection of established nanotherapeutic platforms. Nanoparticles approved for use in Norway 
includes Abraxane, albumin-particle bound paclitaxel, used against multiple cancers and 
SonoVue, a phospholipid stabilized microbubble, used as an ultrasound contrast agent (38-40). 
 
Figure 1.4 - A collection of various nanoparticles in therapeutic use. The figure illustrates nanoparticles 




For simplicity, the term nanocarrier (NC) will be used to describe all nano-sized drug 
delivery systems. Active ingredients can be encapsulated and protected inside the NCs, like 
liposomes, or attached on the outside, like for antibody-drug conjugates (38, 41). Advantages 
of utilizing NCs in drug delivery include the possibilities of targeted drug delivery and 
stabilizing active substances (42). Chemically unstable drugs or substances with poor water 
solubility can be encapsulated in NCs, for example liposomes, to improve bioavailability (43). 
NCs can also be used to ensure that active ingredients reach the drug target at the same time 
and in an advantageous ratio for drugs composed of multiple substances, for example the 
liposome Vyxeos (34, 44).   
Cytostatics is an example where NCs as a DDS can be advantageous because encapsulation of 
the toxic compounds can reduce the severe side-effects associated with cytostatic treatment. 
Cytostatics are often administered in intravenous or oral form, leading to the cytotoxic and 
cytostatic agents being distributed throughout the body, impacting both healthy and cancerous 
tissue (41, 43). NCs can minimize the toxic compounds’ interaction with healthy tissue, 
decrease drug resistance and improve targeted distribution. The NC can protect the drug from 
being prematurely metabolized or eliminated and being engulfed by the immune system (41, 
42).  
The circulating half-life can be extended by producing the NCs of biocompatible material to 
avoid triggering an immune response and thus increase the probability of making contact with 
the target of unhealthy cells (28, 42). Introducing targeting ligands on the NC contributes to it 
reaching specific receptors expressed on the surface of the cancer cells (14, 45). An example 
of this is immunoliposomes decorated with monoclonal antibodies binding to antigens on the 
surface of cancer cells (14). This can prolong the circulation time and therapeutic window by 
increasing the selective uptake and thereby reducing the needed dosage-effect ratio (37, 41, 
42). 
Introducing the inert polymer poly(ethylene glycol) [CH2CH2O]n (PEG) on the outsides of NCs 
will mask them from the immune system, thus avoiding opsonization and further macrophagic 
phagocytosis (10, 38). PEGylation will also keep the liposomes from agglomerating, as well 
as extend drug circulation time (46). Agglomeration leads to particles of dissimilar sizes and 
different drug concentrations, causing it to behave unexpectedly and uncontrollable in the 
body. Doxil/Caelyx was the first liposomal injection formula containing Doxorubicin (DOX) 
which utilized PEGylated liposome technology to improve biocompatibility, approved in USA 
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(33, 38). Studies of the drug showed that the area under the curve (AUC) was increased more 
than 60-fold compared to free DOX, providing higher probability of the liposomes reaching 
the target of interest (47). It was also shown that the volume of distribution for the PEGylated 
NC’s is almost identical to the blood volume, indicating that the drug is almost exclusively 
present in the circulation and very little in the tissue (48). The drug half-life and circulation 
half-life was increased compared to free DOX (47). A disadvantage of PEGylating liposomes 
is the association with dose- and frequency related hand-and foot syndrome which is shown to 
be higher compared to non-PEGylated liposomal formulations (14, 49). However, this might 
be explained by the PEGylated liposomes circulating longer compared to the non-PEGylated 
liposomes. 
 
1.2.1. Liposomes  
Liposomes are unilamellar vesicles in which an aqueous volume is enclosed by a membrane 
composed of lipids (50). Figure 1.5 illustrates a liposome where phospholipids with hydrophilic 
heads and hydrophobic tails form a bilayer. Compared to micelles, which consists of a single 
layer of lipids forming a hydrophobic core, liposomes will have both hydrophilic and 
hydrophobic hollows. These properties make them appropriate NCs for transporting both 
hydrophilic and lipophilic drugs and compounds (51). An example of a phospholipid used to 
produce liposomes is illustrated in Figure 2.3.  
 
 
Figure 1.5 - Illustration of a liposome. A cross section of a liposome with the lipid’s hydrophobic tails illustrated 
in light brown forming a lipophilic hollow, and the hydrophilic heads forming an aqueous core. Figure modified 
from Herfindal, Nilssen (52).  
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To overcome problems with instability, liposomes can be modified by enclosing cholesterol 
(Chol) into the membrane (50). Chol will make the membrane more rigid and thereby more 
stable in terms of leakage. Heat will make the membrane more permeable. By knowing the 
phase transition temperature, liposomes can be modified to ensure release of an incorporated 
compound at a desired temperature.  
The diameter size of liposomes can vary from tens of nm to several µm (37, 41). For medical 
purposes, it has been shown that liposomes with diameters around 150-200 nm remain in the 
bloodstream longer than those with diameters below 70 nm or above 300 nm (53). A 
compromise must thus be made between increased drug capacity and a higher degree of 
accurate targeted drug delivery. Generally, smaller liposomes will have reduced drug loading 
capacity compared to larger liposomes. However, experiments in rodents show that smaller 
particles evade the bloodstream and penetrate into the tumor interstitium to a higher degree 
than larger particles. The accumulation of NCs in the tumor interstitium is explained by the 
enhanced permeability and retention (EPR) effect. (53-56). The EPR effect is the accumulation 
of molecules inside the tumor because of its pathophysiological properties. The 
pathophysiological properties within the tumor typically include leaky vasculature and lack of 
lymph drainage caused by unorganized growing in epithelial tissue (14). However, preliminary 
studies in the clinic have shown that the EPR effect is tumor dependent and there are substantial 
individual differences between patients (56).  
In earlier research on DNR incorporated into liposomes, the liposomes have been 
approximately 120-130 nm to secure both an acceptable amount of drug incorporation and 
enough time spent in the bloodstream (23). The previously mentioned Vyxeos is a non-
PEGylated formulation with a liposome size around 100 nm (17). Vyxeos, showing a more 
positive outcome compared to free DNR and ara-C for t-AML and AML-MRC, gives hope for 
other liposomal formulations containing DNR to further improve the treatment of AML (17).  
 
1.3. Choice of compounds  
Previous research has shown that DNR in combination with a protein synthesis inhibitor 
(cycloheximide or emetine (EME)) have an increased effect compared to DNR alone (23, 57).  
Exploiting this synergism can lower the needed dose-effect bar and thereby give fewer dose-
related side-effects, such as myelosuppression (58). The synergism has earlier been tested both 
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as free drugs and incorporated into liposomes and has shown to enhance anthracycline-induced 
AML cell death in vitro and in small animal models (23, 57). Further research has shown that 
administering EME 30 minutes after DNR would increase the advantageous effect (23). This 
led Dr. Fabrice Anizon at the University of Clermont Auvergne to formulate an analog of EME, 
FG1181, shown in Figure 1.7 B. The rationale behind this molecule is that the liposomes will 
ensure that the two drugs will interact with the blasts at the same time in an optimal ratio. 
Conversion of FG1181 into EME will ensure that it is active 20-30 minutes after DNR is 
released. This delayed activation is believed to ensure the desired time difference between 
DNR and EME. The liposome will protect FG1181 from being metabolized in the blood. 
Liposomal inclusion of the two compounds would be advantageous as it ensures that both the 
active substances reach the same target simultaneously. Liposomal incorporation will also 
ensure equal pharmacokinetics for both compounds, which cannot be achieved if they are 
administered in separate formulations. Combining the compounds in the same liposomes will 
also reduce the amount of liposomes needed and thereby decrease the risk of liposomal toxicity 
such as foot-hand syndrome.  
 
1.3.1. Anthracyclines  
Anthracyclines are a class of cytostatic agents with multiple suggested mechanisms of actions 
(59, 60). The main hypothesis is that anthracyclines intercalate in deoxyribonucleic acid (DNA) 
and inhibits topoisomerase II, thereby halting mitosis (61). Another effect of anthracyclines is 
cellular loss of histones, delaying DNR repair in cancer cells (59). Further, anthracyclines 
generate free radicals which also induce DNA damage as well as damage proteins (62). All the 
above would affect rapidly dividing malignant cells but also affect several non-malignant cells, 
leading to the many drug-related side-effects associated with this drug class (6, 61).  
The major dose-limiting toxic side-effect of anthracyclines include myelosuppression and 
cardiotoxicity (14, 58). Especially for DOX, the risk of developing cardiomyopathy and 
congestive heart failure is increased because of the drug causing severe local tissue necrosis 
(62). Other drug-related side-effects include alopecia, nauseating and vomiting (63). The risk 
for cardiotoxicity, myelosuppression, vomiting and alopecia is shown to be significantly lower 
when incorporating DOX into PEGylated liposomes (63).  
The first anthracyclines, DNR and DOX, were isolated in the 1960s and the group has the 
broadest range of clinical use in oncology compared to other antitumor drugs, with only a few 
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cancers known to be unresponsive to treatment (58, 60, 64). Figure 1.6 shows the molecular 
structure of DNR (58). The anthracyclines have fluorescent properties because of its 
anthraquinone structure, facilitating easy detection in biological samples (65). DOX is still the 
most commonly used anthracycline in solid tumors, and DNR is generally used against 
hematological cancers as it currently shows the best results of the available treatment agents 
available (58).   
 
Figure 1.6 – The molecular structure of DNR. The drug is amphiphilic and amphoteric, containing a lipophilic 
anthracycline ring, hydrophilic hydroxyl groups, an acidic ring phenolic group and basic and lipophilic sugar 
amino groups (66). Figure adapted from Cortés-Funes and Coronado (58). 
 
Several anthracycline analogs have been developed in the hope of reducing the drug-related 
side-effects (58). These analogs have some advantages in comparison to the original 
anthracyclines, but less than anticipated during development. IDA is in some cases used in the 
“7+3” regime as a replacement for DNR and is the only anthracycline available for oral 
administration (58). IDA shows a broader spectrum of activity compared to DNR and is used 
against breast cancer as well as AML, but has the same severe side-effects as DNR (58). 
Epirubicin is shown to be less cardiotoxic compared to DOX, and shows increased effect 






1.3.2. Emetine and analogs  
Emetine (EME) shown in Figure 1.7 A, is a protein synthesis inhibitor derived from the plant 
ipecac (Carapichea ipecacuanaha) and is already approved for use in humans against protozoal 
infections (68, 69). The compound is a powerful emetic and expectorant, and inhibits the 
replication of DNA and RNA in viruses (70). EME is highly toxic to all cells and can be 
modified for use in targeted cancer treatment (71). The compound has relatively equal toxic 
profile across species, which helps in further investigations and drug development (23).  This 
is an advantage when it comes to cancer therapy because research on cells and small animal 
models can be translated to cancers in a high degree. 
 
 
Figure 1.7 – EME and FG1181. Molecular structures. A, and B, EME and the analog N2-acetoxymethyl-emetine, 
termed FG1181. The substituent side chain on the secondary amine is marked in green.  
 
A hypothesis is that exchanging the hydrogen on the N-2’ secondary amine of EME with a side 
chain can lead to an inactivating of the molecule (71). In vivo toxicity and anti-cancer activity 
with EME derivatives were tested with prostate specific antigen activation in 2017, and it was 
shown that modification with a non-toxic side group can render a non-toxic prodrug with a 
“cytotoxic switch” (71). The analog N2-acetoxymethyl-emetine termed FG1181, is shown in 
Figure 1.7 B. This is a modified version of EME where the hydrogen on the N-2’ secondary 
amine is substituted with a methylene diacetate side chain (green circle in Figure 1.7 B). The 
hypothesis is that when the side chain is cut off, the molecule will be metabolized to EME and 
thereby activated. This is estimated to happen 20-30 minutes after the liposome frees the 




The aim of this study was to find an improved treatment method for AML by combining DNR 
and FG1181 in a liposomal formulation. This can further be divided into three sub-aims. 
Firstly, to verify and identify the biological activity of FG1181 and compare its properties to 
that of EME.  
Secondly, to produce a liposomal formulation containing FG1181, both alone and in 
combination with DNR.  
Thirdly, to evaluate the effect of liposomal formulation containing DNR and FG1181 compared 
to liposomal formulations containing DNR and EME.  
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2. Experimental theory 
2.1. Spectroscopy 
Spectroscopy is the study of matter emitting and absorbing radiation, and particles interacting 
(72).  This includes the study of ultraviolet (UV) light, infrared (IR) light, radio waves, x-rays, 
gamma-rays and visible light, among others (72). Spectroscopy can be utilized to investigate 
molecular properties such as molecule size and structure, and are used as an analytical method 
in multiple fields including physics, biology, chemistry etc.  
 
2.1.1. Dynamic light scattering 
Dynamic light scattering (DLS) is a technique where the light scattered of a molecule is 
measured, allowing specific properties of the molecule to be studied (73). The light will interact 
with particles, where small particles with size ~0.3-10 000 nm (depending on the laser and DLS 
machine) can be detected as undergoing Brownian motion (74). Brownian motion is the 
continuous diffusion of a particle when suspended in a fluid as illustrated in Figure 2.1 (75, 
76).  
 
Figure 2.1 - A particle undergoing Brownian motion. The arrow shows which way the particle, marked in red, 
moves. The apparently random route is termed Brownian motion. Figure adapted from Leybold® (77). 
 
The relationship between the particles’ measured Brownian motion can be converted to size 
and size distribution with the Stokes- Einstein equation shown in Equation 2.1 (78). In the 
equation, DT is the diffusion, kb the Boltzmann constant, T the temperature, η is fluid viscosity 




The DLS measures diffusion by exposing the sample to a monochromatic wave of light and 
has photon detectors on all sides measuring light intensity (79). The particles’ constant motion 
will cause a small change in wavelength frequency between unscattered and scattered light, 
termed a Doppler shift (79). As larger particles move slowly, these will cause a small Doppler 
shift, while the smaller ones exhibit a larger, more easily detected shift. The light intensity is 
measured for a period and processed into a mathematical function, identifying patterns where 
the exponential decay is constant. This gives the diffusion constant, DT, making it possible to 
calculate the sphere diameter, d.(79). 
A disadvantage to the DLS is that it measures size indirectly, and that the resulting diameter 
assumes that the particles are spheres. It also depends on high purity of the samples. Further, if 
the samples are polydisperse, i.e. that they consist of several size-populations, DLS may not be 
able to accurately determine individual size-populations, or average size. Therefore, the 
polydispersity index (PdI), the size population, is given in combination with measurements. 
However, for routine measurements of liposomes, DLS is a reliable method. Liposomes are 
spherical, do not interact with the reflected light and the measurements are quick and easily 
performed. 
 
2.1.2. Infrared spectroscopy 
IR spectroscopy measures the absorption of radiation when passing infrared light (700-1000 
nm) through a sample (80). An advantage for IR spectroscopy is that it can be used to examine 
liquids, solids and gases, depending on the instrument and its settings (72). The bonds in 
molecules and atoms can vibrate in different ways, divided into the subtypes stretching and 
bending (80). These subtypes can further be subdivided into symmetric and asymmetric 
stretching, and the bending subtypes into scissoring and rocking. Figure 2.2 illustrates a 
molecule undergoing symmetric stretching.   
 
Figure 2.2 - Illustration of a molecule undergoing symmetric stretching. Symmetric stretching of the carbon- 
hydrogen along the bonds. The red hydrogen atoms stretch to and from the carbon atom at a given frequency 
making it possible to identify this part of the molecule by IR measuring. Figure adapted from Stuart (80). 
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As different molecular bonds vibrate with different frequencies, IR measuring can be used to 
identify the presence of a structure, for example lipids (81). Lipid content can be identified by 
the vibration of carbon-hydrogen symmetric stretching at ~ 2850 cm-1 (80). Figure 2.3 indicates 
one of the methylene bonds in the phospholipid hydrogenated egg phosphorylcholine (HEPC), 
making it possible to identify it as a lipid. The resulting peaks at a given energy in an absorption 
spectrum will correlate to frequencies of a vibrating covalent bond in a molecule (80). IR 
detection can be used for quantitative analysis as well as for the qualitative analysis described 
by preparing a calibration curve and comparing the measurements of a sample with unknown 
concentration.   
 
 
Figure 2.3 - Hydrogenated egg phosphatidylcholine (HEPC). A phospholipid with one of the discussed 
methylene bonds marked red. Only one out of 34 methylene bonds are marked for simplicity. Figure adapted from 
Avanti® Polar Lipids (82).  
 
2.2. Western blotting  
Western blotting is a technique for detection and quantitation of proteins (83, 84). The 
technique uses three elements, protein separation by size, transfer of proteins to a solid 
membrane and target marking with primary and secondary antibody to visualize and quantitate 
proteins of interest (85). Here, cells were incubated with different compounds, rinses for excess 
compound, lysating the cells to get all protein in a mixture. The lysate was rinsed from the cell 
components by centrifugation. To separate by size, the cell lysates, are separated 
electrophoretically on SDS polyacrylamide gels where an electric force makes the negatively 




The protein is further blotted to a polyvindylidene fluorene membrane before being blocked to 
prevent non-specific binding of applied antibodies. The primary antibody is specific to the 
protein of interest, and the secondary antibody is specific to the source of the primary antibody. 
The secondary antibody is often conjugated with an enzyme which will give a signal detectable 
for the binding. The antibodies will present themselves as bands, where the thickness of the 
band corresponds to the amount of protein present (85). At last, a loading control is used, for 
instance anti-β-actin, to control that equal amounts of protein are loaded into each well.  
 
2.3. Chromatography 
Chromatography is a collective term for analytical separation (87). The technique is used to 
separate and purify analytes based on properties like size, charge and hydrophobicity to 
mention a few (88). The technique is used for quantitative and qualitative analysis by injecting 
the mixture into a two-phase separating system. One phase is a stable stationary phase, while 
the other is a mobile phase aiding the analytes through the stationary phase. The mobile phase 
can be a gas or a liquid. Differences in the properties of the analytes and their interactions with 
the phases lead to the molecules being eluted separately.  
 
2.3.1. Size exclusion chromatography  
Size exclusion chromatography (SEC) separate analytes based on their sizes (89). The 
technique is also known as gel-filtration chromatography. The stationary phase consists of 
porous particles, for instance cross-linked dextran polymer gel. Small analytes diffuse into the 
pores, while larger analytes pass on the outside of the particles (87). The analytes which pass 
through the porous particles will be retained, and thus elute at a later point compared to the 
particles that are too large to enter the pores. Figure 2.4 illustrates the process of size exclusion 
chromatography. A segment of the column is enlarged and a porous particle, encapsulating 
multiple small and medium analytes in its pores, is shown. The particles will exit the column 







Figure 2.4 - Illustration of Size exclusion chromatography (SEC). A sample containing large (purple), medium 
(brown) and small (gold) analytes are added to a column with porous particles. The segment shows how the 
particles encapsulate the smaller and medium analytes while the larger pass on the outside. This happens multiple 
times throughout the column, causing the delayed elution. 
 
An important consideration when performing SEC is the ability to accurately separate the 
different particles as they emerge from the column. This can be done by visually inspecting 
whether the analytes emerging from the column differ in color, or by fractionation. It is also 
important to choose the right packaging materials because the analytes are separated based on 
the material’s pore size (89). A larger pore size leads to larger analytes diffusing into the pores.  
 
2.3.2. High-performance liquid chromatography   
High-performance liquid chromatography (HPLC) is an analytical technique using high 
pressure to accelerate the process of liquid chromatography (90). The mobile phase is a 
combination of two or more liquids. The stationary phase is a column consisting of fine 
particles with diameters ≤ 5 µm (87). The column has higher resolving power if the particles 
are finer, but this increases the back pressure of the column. These particles form a matrix, 
which the added sample are eluted through via the mobile phase.  
The most common stationary phases are normal and reversed phase, with polar or non-polar 
stationary phase, respectively (90). The most commonly used method in drug analyses is 
reverse phase HPLC (RP-HPLC), where non-polar analytes react with the non-polar functional 
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groups on the stationary phase. RP-HPLC is often used as the mobile phases can consist of 
simple, inexpensive and safe components, the elution order is easily predicted based on 
hydrophobicity and the column is reasonably stable (90). Commonly used mobile phases 
include water, acetonitrile or methanol. The most commonly used reverse phase columns are 
octadecylsilane (C18) columns. To prolong the life of the main column and prevent the column 
from clogging, a guard column can be used (90). The guard column should have a small internal 
volume to minimize peak broadening.  
Ultraviolet (UV) light is emitted through the detector, and as the UV radiation is absorbed by 
the sample components, the detector observes a reduced signal (90). The UV detector can be 
set to measure at a fixed wavelength, at variable wavelengths or with a diode array that 
measures a spectrum of wavelengths simultaneously. The resulting peaks can be further 
analyzed as wanted. 
 
2.4. Membrane permeability 
The parallel artificial membrane permeability assay (PAMPA) is a model for measuring 
passive diffusion across a membrane (91). An artificial membrane can be used to characterize 
a compound’s ability to passively diffuse across physiological membranes, for instance the 
blood-brain barrier or liposomal membranes (92). This is an important part of drug delivery 
development, because some drugs, for instance Daunorubicin (DNR), is known to be a 
substrate for active transport over membranes (93). This means that for DNR to cross the 
liposomal membrane, the temperature must exceed the phase transition temperature.  
Membranes for PAMPA can be purchased premade or be individually adapted to a specific 
assay by adding cholesterol. A setup can for instance consist of a plate with 96 wells with 
membranes of 0.45 µm pores made of Polyvinylidene fluoride (94). The bottom plate consists 
of donor wells filled with samples diluted in buffer. The top plate is placed onto the bottom 
plate. The top plate has a semipermeable membrane in the bottom of each well, which each are 
filled with buffer solution. The drugs can passively diffuse through the membrane into the 
acceptor wells, but not back to the donor wells. This is indicated by the one-sided arrows in 
Figure 2.6 which illustrates a well in a PAMPA plate. After 4-5 hours of incubation, acceptor 
and donor wells are analyzed to find effective permeability, log(Peff). A definition gives 
measured log(Peff)  < -6.14 as impermeable, -6.14< log(Peff) < -5.66 as low permeability and -
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5.66 < log(Peff) < -5.33 as intermediate permeability (95). Log(Peff) over < -5.33 are considered 
as highly permeable. An advantage when performing PAMPA is that it is easy, but it is 
important to consider the shortcomings- including the possibility of incorrect predictions and 
reproducibility difficulties (91).  
 
               
Figure 2.6 - Well in PAMPA-plate. The small purple particles indicate a drug able to diffuse through the 
membrane, while the yellow particles are a drug which cannot passively diffuse through the membrane. Figure 
adapted from Creative Bioarray (96). 
 
2.5. Assessment of cellular cytotoxicity 
In vitro assessments are necessary to carry out before conducting in vivo trials, but it is 
important to note that these will give different results. In vivo assays are more controlled, not 
including factors like the human immune systems. The use of knockout mice as models for 
cancer, for instance, does not take into consideration the fact that germline mutations often lead 
to embryonic or early postnatal death (97). Some cancers in humans are triggered by a somatic 
mutation leading to a centered tumor growth, while whole-body gene knockout mice can have 
the mutation in every gene. The in vitro assessments give valuable information regarding 
further development, but the results must be critically reviewed before concluding that the 
results apply for human cancers. 
 
2.5.1. Cell lines 
The use of cell lines for in vitro cell assessments gives the opportunity to test a compound on 
a specific cell type. However, the effect on healthy cells and the immune system’s response is 
not measured when testing a cytotoxic compound on a malignant cell line. Chemotherapy is 
known to damage the host immune cells, leaving the immune system impaired to fight 
remaining cancer cells and inhibit tumor growth (98).  
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The cell lines used in this study includes malignant and non- malignant cells, with a focus on 
the monocytic leukemia cell line MOLM13 (ACC, 554) (99). MOLM13 was collected from a 
human 20-year old male diagnosed with the AML subtype FAB M5a after relapse in 1995 
(100). The non-malignant cell lines NRK (ATCC, CRL-6509) and H9c2 (ATCC, CRL-1446) 
were used as non-malignant comparisons (99). NRK cells are rat kidney fibroblast cells (101). 
H9c2 cells are rat heart/myocardium myoblast cells (102). The non-malignant cell lines can be 
used to estimate a compound’s effect on non-mutated human cells and thereby drug-related 
side-effect. 
 
2.5.2. Assessment of cell viability 
Cell viability can be estimated using metabolic activity indicators. An example of this is 
performing colorimetric assays utilizing water soluble tetrazolium salt-1 (WST-1) as a 
proliferation agent (103). A colorimetric assay determined the metabolic activity in a sample 
by comparing the colored substances relative to control (104). The stable tetrazolium salt WST-
1 is cleaved enzymatically by NAD(P)H (noted as EC in Figure 2.5) reductase to a soluble 
formazan dye as shown in Figure 2.5. The formazan has a dark red color, thus making it 
possible to use a spectrophotometer to measure absorbance. The amount of formazan dye 
formed directly correlate to the number of metabolically active cells in cell culture, making it 
possible to estimate metabolic activity relative to untreated control cells (103).  
 
Figure 2.5 - Illustration of a cell proliferation reagent reaction. WST-1 is being reduced to Formazan. The 
WST-1 reagent has a slightly red color, while the Formazan is dark red. Formazan enters the nucleus, coloring it 
red. Figure adapted from product sheet at Merck (103).  
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A disadvantage of using the WST-1 colorimetric assay is that substances of strong (red) colored 
compounds can influence the spectrophotometer by giving a higher reading for metabolic 
activity. This makes it necessary to visually check the wells to ensure correct results. A 
fluorescence microscope can be used if the cells are stained with a fluorescent stain, for instance 
Hoechst 33342 which will color DNA blue (105). However, visually confirming if cells are 
normal or apoptotic can be difficult to accurately quantify. Combining the two methods of 





3. Materials and methods 
3.1 Materials and reagents 
FG1181 precured from Dr. Fabrice Anizon (University of Clermont Auvergne, France). 
1,2-Disteraoyl-sn-glycero-3-Phosphoetanolamine-N- [Methoxy(Polyethylene glycol)-2000] 
(ammonium salt) (DSPE-PEG), Whatman® Nucleopore Track- Etched membrane filters and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[folate(polyethylene glycol)-5000]  
(ammonium salt) (DPSE-PEG(5000)folate) from Avanti ® Polar Lipids (Alabaster, AL, USA). 
Quick StartTM Bradford 1x Dye Reagent (12% 10 well), 50 µL/well Mini-Protean® TGX™ 
Precast Gels, Precision Plus Protein Standard, immune-Blot® PVDF Membranes for Protein 
Blotting, 10x Tris/Glycine (TG) buffer and 10x Tris/Glycine/SDS (TGS) buffer from Bio-rad 
(Hercules, CA, USA). 
Corning® GentestTM Pre-coated PAMPA Plate system from Corning® (Corning, NY, USA). 
Chloroform and Dimethyl sulfoxide (DMSO) ≥ 99.5% from Honeywell chemicals (Morris 
Plains, NJ, USA). 
Hydrogenated egg phosphatidylcholine (HEPC) from Lipoid GmbH (Ludwigshafen, 
Germany). 
Sephadex™ G-50, ≥ 99.5% sodium chloride, cholesterol (Chol), ammonium sulphat, 
phosphate buffered saline (PBS), hydrochloric acid, sodium hydroxide, emetine (EME), 
trifluoroacetic acid (TFA), 37% formaldehyde,  0.01 mg/mL Hoechst 33342, RPMI medium, 
Dulbecco's modified Eagle's medium (DMEM), Penicillin, Streptomycin. L-Glutamine 
solution (L-glut), fetal bovine serum (FBS), Tween ® 20, ≥ 99.9% Trizma ® base (TBS), ≥ 
99.8% methanol, Ponceau S solution, Bromophenol Blue sodium salt, NP-40%, EDTA, DTT, 
NaF, MgCl2*6H2O, 86-89% glycerol solution, ≥ 99.9% Acetonitrile (ACN) and ≥ 99.9% 
Methanol for HPLC from Merck (Darmstadt, Germany). *Earlier Sigma/ Sigma-Aldrich (St. 
Louis, MO, USA). 
WST-1 Cell Proliferation Assay Reagent and cOmplete tablets, Mini EDTA-free EASYpack, 
protease Inhibitor Cocktail Tablets from Roche Applied Science (Penzberg, Germany). 
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UltraCruz® suspension culture bottles with vent cap from Santa Cruz Biotechnology, Inc. 
(Dallas, TX, USA). 
DNR (Cerubidine) from Sanofi Aventis (Lysaker, Norway).  
96-MicroWellTM plates with flat bottoms, NuncTM 12-well multidishes, PierceTM Bovine Serum 
Albumin Standard, Tropix® I-block™, SuperSignal® West Pico Chemiluminescent Substrate 
and West Pico PLUS chemiluminescent Substrate from Thermo Scientific (Waltham, MA, 
USA). 
 
3.2 Equipment and instrumentation 
DLS was measured with a Zetasizer Nano XS from Malvern Panalytical (Almelo, Netherland). 
The IR spectroscopy was performed with Direct Detect Assay-free Cards on a Direct Detect ® 
Spectrometer from Merck Millipore (Darmstadt, Germany). SEC was performed with an 
Econo- Column from BioRad (Hercules, CA, USA). Extrusion was performed with a mini 
extruder from Avanti ® Polar Lipids (Alabaster, AL, USA) and a LIPEX™ gas extruder from 
Northern Lipids (Burnaby, Canada). The fluorescence microscope used was a Diaphot 300 
Inverted Microsope from Nikon (Minato, Tokyo, Japan). 
HPLC was performed with a Merck-Hitachi LaChrome HPLC machine from VWR 
(WestChester, USA), consisting of a Merck L-7614 pump, a Rheodyne® 7725i manual 
injector, 250 µL 1725N syringe from Gastight® from Merck*(Darmstadt, Germany), a 
Kromasil 100-5C18 150-4.6 mm reverse phase column (Akzo Nobel, Sweden), a L-7455 diode 
array detector, Hitachi Interface D-7000 and the data processing software D-7000 HPLC 
system Manager (HSM) version 4.1. *Earlier Sigma/ Sigma-Aldrich (St. Louis, MO, USA) 
The thermomixer comfort was from Eppendorf AG (Hamburg, Germany), the Zentrifugen 
universal 32 centrifuge from Hettich (Tuttlingen, Germany), the humidified Steri-Cycle CO2 
incubator from Thermo Scientific (Waltham, MA, USA), the Olympus CKX31 microscope 
(Shinjuku, Tokyo, Japan), 2103 Envision Multilabel Plate Reader from PerkinElmer(Waltham, 
MA, USA), the Allegra™ X-22R Centrifuge from Beckman Coulter (Brea, CA, USA), the 
ImageQuant LAS 4000 camera system from GE Healthcare (Chicago, IL, USA) utilizing the 
program “Image Quant LAS400”, the Mini-Protean® Tetra system blotting chambers from 
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BioRad (Hercules, CA, USA) and the Scanlaf Laminar Air Flow (LAF) Mars safety benches 
from Labogene (Allerød, Denmark). 
 
3.3 Production of liposomes 
3.3.1 Preparation of liposomes   
HEPC, Chol and DSPE-PEG were dissolved in chloroform at concentrations of 2.37 mg/mL 
HEPC, 0.65 mg/mL Chol, and 0.71 mg/mL PEG-PE.  Ten mL from each of the stock solutions 
were mixed in a 200 mL round bottom flask, giving a molar ratio of 1.81 HEPC: 1 cholesterol: 
0.15 DSPE-PEG. For the production of folate decorated liposomes, DSPE-PEG(5000)folate 
was added at one tenth of the molar concentration of DSPE-PEG by adding 10 mL 0.16 mg/mL 
DSPE-PEG(5000)folate dissolved in chloroform to the round bottom flask in addition to the 
other lipids. 
A lipid film was produced by evaporation of the chloroform using a rotary evaporator at 200 
mbar and 60 RPM for 60-90 minutes without heating and then at 20℃ using a water bath until 
the film appeared dry. Residual chloroform was removed by running the vacuum pump at 
maximum pump capacity (7-8 mbar) for 30 minutes. The film was hydrated with 10 mL 250 
mM ammonium sulphate adjusted to pH 6-6.5 and heated to 60-65℃. To completely hydrate 
the lipid film, it was thoroughly vortexed at 60℃ until no lipid film was visible on the round 
bottomed flask. This produced large multilamellar vesicles (LMV) which were further extruded 
to produce small unilamellar vesicles, also called liposomes.  
Extrusion was performed by using a mini syringe-extruder for small volumes, or a gas extruder 
for large volumes. For the mini extruder, the LMV suspension were passed through 19 mm Φ 
membrane filters with decreasing pore size. The suspension was passed 11 times through 400 
nm filters, 11 times through 200 nm filters and finally 22 times through 100 nm filters. The gas 
extrusion was performed with 25 mm Φ membrane filters 5 times through 800 nm filters, 5 
times through 400 nm filters, 10 times through 200 nm filters and 10 times through 100 nm 
filters. This ensured liposomes with diameter of approximately 115-135 nm and acceptable 





SEC with degassed PBS adjusted to pH 8.0 was performed to change the buffer around the 
liposomes (see experimental theory section, chapter 2.3.1). If the column was left unused for 
more than a month, empty liposomes were sent through before use. The liposomal formulation 
was stored at 4℃ in the dark for up to nine days before being used in experiments and shaken 
vigorously before every use. The lipid content was measured using IR spectroscopy and 
calculated using a previously obtained standard curve with equation 3.1 where y are the 
readings from the IR spectroscope, and x the lipid concentration in mg/mL (see experimental 




3.3.2 Compound loading of liposomes 
FG1181 was dissolved in DMSO, DNR and EME were dissolved in PBS. The liposomes were 
loaded with 1:10 DNR: lipid solution and/or 1:5 or 1:10 EME or FG1181 compound/lipid 
content by two methods, either leaving the solution in the dark at 4℃ overnight or under stirring 
for one hour at 60℃. After loading, the liposomes went through SEC to remove non-
encapsulated compound, the lipid contents were measured with IR and the sizes measured with 
DLS. 
 
3.3.3 Reverse phase high performance liquid chromatography 
Reverse phase high performance liquid chromatography (RP- HPLC) was used to separate and 
quantify the compounds in the liposomal formulations with equipment specified in the 
equipment and instrumentation chapter 3.2. Ten µL samples were loaded onto the column. The 
samples used were dissolved in 30% ACN and MilliQ (MQ). Two set ups for mobile phase 
composition and gradients were used. The gradients of the components are plotted in Figure 
3.1. The first mobile composition, A1 and B, were A1: 2:8 MeOH:MQ added 0.05% and B: 
ACN added 0.005% TFA. The second, A2 and B, were MQ added 0.05% TFA and B ACN 
added 0.005% TFA. Spectra from 190-550 nm were recorded every 0.2 sec, and integration of 




Figure 3.1 – Mobile phase gradients. Scheme of the percentage of each component in the mobile phases. Note 
that the gradients extend over different time periods. 
 
3.4 Parallel artificial membrane permeability assay  
Parallel artificial membrane permeability assay (PAMPA) was performed to estimate if and to 
which extent FG1181 and EME passively cross over a phospholipid membrane. The assay was 
performed according to the manufacturer’s instructions. In brief, the compounds were 
dissolved to 50 µM in buffer, and added to the donor wells. The membrane plate was added, 
and buffer added to the acceptor wells. The buffers were PBS pH 7.4 or pH 8.0 in the donor 
wells and PBS pH 7.4 or 250 mm ammonium sulphate pH 6.4 in the acceptor wells. This would 
mimic the pH conditions during compound loading of liposomes. After assembly of the plate, 
it was left in the dark at room temperature for 5 hours before the constituents of the donor and 
acceptor wells were collected and the compound content analyzed by HPLC as described in 
section 3.3.3. The compounds were tested both alone and in combination under the different 
pH conditions.  The ratio between drug in the acceptor wells and donor wells were calculated. 
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The effective permeability, Peff, [cm/s] was calculated using Equation 3.3, where A is the area 
of the filter plate membrane, VD and VA are the volumes of the donor and acceptor wells, CA(t) 
is the concentration in the acceptor well at time t, and t is the time of incubations (107). Ceq 
was calculated using Equation 3.4, where CD(t) is the concentration in donor well at time t. 
 
 
3.5 Cell maintenance and experiments 
3.5.1 Cell maintenance 
The MOLM13 cell line are suspension cells which were cultured in RPMI-1640 growth 
medium, enriched with 100 IU/mL penicillin, 100 mg/L streptomycin, 0.2 mM L-Glut and 10% 
FBS. NRK and H9c2 are adherent cell lines which were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM), enriched with 100 IU/mL penicillin, 100 mg/L streptomycin and 
10% FBS. The cells were incubated at 37℃ in the dark with 5% CO2 in the air. The H9c2 and 
NRK were detached from the incubation flask by washing twice with room temperature PBS 
and incubating with 0.33 mg/mL trypsin for 2-3 minutes at 37℃. To resuspend all the cell 
lines, the cells were centrifuged at 200xG for 3 minutes and the cell pellet reseeded in fresh 
medium. All cell handling was performed in a LAF bench and inspected in a microscope.  
 
3.5.2 Metabolic activity measurements 
Dose-response assays were performed with 100 µL medium as blanks, and 50 µL medium and 
50 µL cells of approximately 400 000 cells/mL as control. Ten µL drug or 20 µL liposomal 
solutions were mixed in 80 µL medium before being sequentially diluted in 50 µL medium 
across the plate. 50 µL cells were added to all wells except the blanks. All parallels were carried 
out in triplets, including blanks and controls. The wells on the edges of microplates were not 
used for cells but filled with sterile liquid to avoid edge effect due to for instance liquid 
evaporation. 96-well microplates were used to carry out all cell assays. The plates were 
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incubated at 37℃, 5% CO2 for 22-24 hours. Ten µL WST-1 Cell Proliferation Reagent was 
added to each well and the plate was further incubated for two hours (see chapter 2.5.2). The 
plate was then analyzed using a spectrophotometer measuring absorbance at 450 nm, with a 
reference read at 620 nm. The measurements were adjusted relative to blanc and control with 




To visualize the nuclei of the cells, 100 µL 4% Fix, consisting of 4% formaldehyde and 0.01 
mg/mL Hoechst 33342 in PBS pH 7.4, was added to each well. Images were obtained using a 
fluorescence microscope fitted with a camera and the percent of apoptotic, necrotic and normal 
nuclei determined. The pictures were imported to ImageJ to calculate mortality depending on 
drug concentration.  
 
3.5.3 Kinetics assay 
To assess the induction of apoptosis over time, compounds were added to cells, and aliquots 
transferred to 2% formaldehyde in PBS pH 7.4, added 0.01 mg/mL Hoechst 33342 at different 
time-points for 24 hours. To compensate for cell death in the control, the data was adjusted 




3.6 Protein detection 
After one-hour treatment at 37℃ with compounds, MOLM13 AML cells were rinsed twice 
with 4℃ 9 mg/mL NaCl by centrifugation at 1200 RPM for 5 minutes at 4℃. The cells were 
then lysed in 100 µL SHIEH-buffer consisting of 10 mM Tris HCl pH 7.5, 1 mM EDTA, 40 
mM natrium chloride, 10% glycerol, 0.5 % NP-40, 5 mM sodium fluoride, 0.5 mM sodium 
orthovanadate and 1 mM DTT in MQ. The lysis was performed by incubation on ice for 30 
minutes before being centrifuged at 13 000 RPM for 30 minutes at 4℃. 
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To determine the protein concentration of the lysate, a standard curve of Bovine Serum 
Albumin Standard and dye reagent were prepared with concentrations of 0, 2, 4, 6, 8 and 10 
mg/mL according to the manufacturer’s instructions. 2 µL lysate from each sample (described 
in Section 3.9.1) were dissolved in 998 µL dye reagent in Eppendorf tubes. Triplets of 200 µL 
standard curve and samples were prepared on a 96-well microplate and left for more than five 
minutes. The plate was introduced into a spectrophotometer reading at 595 nm, and the protein 
concentration calculated from the equation obtained from the standard curve.  
Before SDS-PAGE, 50 µL samples containing 1 mg/mL protein were prepared in 10% 5x 
loading buffer, consisting of 1% SDS solution, 12 mM Tris-HCl pH 6.8, 0.1% Bromophenol 
Blue, 50mM DTT and 10% glycerol in MQ, and 1 x protease synthesis inhibitor in SHIEH- 
buffer. The samples were heated for 10 minutes at 100℃, before being left on ice for 20 
minutes. Twenty µL of the standard Precision Plus Protein Standard All Blue was added to the 
second well, while the outermost wells were left open. Forty µL sample were introduced in 
every well of a 12% precast gel for 90 minutes on 100 V in an SDS-PAGE chamber with TGS 
as running buffer to transfer the proteins to a polyvinylidene fluoride membrane. The blotting 
was left running for 70 minutes in a blotting chamber at 100 V using a blotting buffer consisting 
of 10% MeOH and 10% TG in MQ. The membrane was thoroughly washed three times in 
TBS-T consisting of 1% TBS and 1% Tween in MQ. 
Ponceau S solution was added to the membrane and the excessive solution washed away with 
MQ to ensure the presence of protein bands. The membrane was photographed (Appendix I) 
before all the Ponceau S solution were rinsed away with 0.1 M Sodium hydroxide and MQ. 
The membrane was thoroughly washed three times in TBS-T. 
The blocking buffer was produced by adding 2.0 g I-Block powder in 1L TBS heat to 70℃, 
cool down to 20℃, add 2.18 g MgCl2*6H2O and 1 mL Tween. The membrane was blocked 
for 60 minutes on a shaker before being washed thoroughly with TBS-T three times. Five mL 
caspase-3 mouse monoclonal IgG2a from Santa Cruz Biotechnology (Dallas, TX, USA) was 
incubated with the membrane on rotation in the dark at 4℃ for 18 hours overnight (108). The 
next day, the membrane was thoroughly rinsed again with TBS-T, before incubation with the 
secondary antibody, donkey anti-mouse horseradish peroxidase (AB2340770, product nr. 711-
035-150) from Jackson ImmunoResearch Europe Ltd (Cambridgeshire, UK) for 60 minutes on 
rotation in room temperature. The antibody solution was removed and washed again with TBS-
T. 2 mL chemiluminescent substrate (SuperSignal™) was applied to the membrane for 3.5 
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minutes and a picture taken with a chemiluminescence and fluorescence digital imaging system 
for gels and blots. The (Appendix I).  
The TBS-T rinsing step was repeated, and the membrane left in mouse anti-β-actin antibody 
(AC-15 (ab6276)) from Abcam (Cambridge, UK) for one hour. The β-actin was removed, and 
the membrane rinsed with TBS-T. 2 mL chemiluminescent substrate (West Pico Plus) was 
added for one minute, and a new picture taken (Appendix I). 
 
3.7 In silico prediction, data analysis and presentation 
In silico prediction was performed by drawing the structures in ChemDraw Professional 
version 16.0 (PerkinElmer Informatics Inc. Waltham, MA, USA) and using the net charge 
prediction plug-in Marvin Sketch version 19.1 (ChemAxon Ltd., Budapest, Hungary).  
Fluorescent images were analyzed with NIH Image J version 1.52a. All data are presented as 
averages with standard deviation (n ≥ 3). The data was processed using Microsoft Office Excel 




4.1 FG1181 chemical properties and anti-AML activity 
Before starting the work with loading the emetine analog FG1181 into liposomes, we needed 
to perform characterization of the chemical properties of the compound, as well as its cytotoxic 
potential. This, to ensure that the compound was a valid drug candidate for AML therapy. In 
silico predictions of net charge as a function of pH could give an indication of the ability of 
FG1181 to cross membranes. These showed that the protonated form was the dominating 
specie below pH 8.5, whereas the molecule became fully uncharged above pH 10.0. Note that 
while EME has a net charge of +2 at acidic conditions, FG1181 only has +1 due to the hydrogen 
being substituted at EME’s secondary amine (green circle in Figure 4.1 A). DNR is negatively 
charged above pH 9.0, and positively charged at pH below 8.5, but there is a pH window 
between 8.0 and 10.0 where the dominating specie of all molecules will be uncharged. This 
suggests that the same conditions for post-loading of liposomes could be used for FG1181 as 
was described for EME and DNR (23). 
 
 
Figure 4.1 – Net charge predictions of FG1181. A, The estimated molecular form of protonated FG1181 with 
the affected amine and added proton encircled red. The protonation leads to the compound getting a net charge of 
+1. The other nitrogen, marked green, indicates the amine where the substituent is attached on EME to produce 
FG1181. Emetine (EME) can be protonated at both the encircled nitrogens, giving a net charge of +2.  B, In silico 
net charge predictions for FG1181, EME and Daunorubicin (DNR), made using Marvin Sketch. 
 
Next, we wanted to verify the findings from the in silico prediction by using PAMPA. Here the 
drug content of the donor and acceptor wells are measured by RP-HPLC, and two sets of 
standard curves for DNR, EME and FG1181 were prepared to be able to quantify the 
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compounds. This was done with different mobile phase composition and gradients, as 
described in the Method section, chapter 3.3.3. The second set of standard curves with 
equations from linear regressions are presented in Figure 4.2. 
 
Figure 4.2 – Standard curves produced with RP-HPLC. A-C, Standard curves for Daunorubicin (DNR), 
emetine (EME) and FG1181, respectively. The given equations were used to calculate compound concentration 
in PAMPA and in compound-loaded liposomes. The standard curves were produced as described in Section 3.3.3 
and Figure 3.1 B. 
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PAMPA was performed to estimate the different compounds’ ability to cross the liposomal 
membrane. In the assay, two different pH conditions were examined. Examples of RP-HPLC 
spectra are shown in Figure 4.3 and the results presented in Figure 4.4 and Figure 4.5. Note 
that in all the FG1181 donor wells, an extra peak at approximately t ~ 5.60 was detected in the 
spectrums. This is marked with a black arrow in Figure 4.3 and as “FG1181*” in Figure 4.4. 
Note that more compound passes the membrane for pH 8.0 in the acceptor wells and 6.4 in the 
donor wells compared to pH 7.4 in both wells. This is particularly evident for FG1181, but 
there is also an increased proportion of DNR and EME in the acceptor wells. In line with this, 
we observed increased permeability (log(Peff)) with pH 8.0 in the donor wells, and 6.4 in the 
acceptor wells compared to pH 7.4 in both wells, as illustrated in Figure 4.5. 
 
 
Figure 4.3 – RP-HPLC spectra of FG1181, emetine (EME) and daunorubicin (DNR) from the PAMPA 
samples. One experiment in the PAMPA with examples of spectra detected from different wells. The arrows 
indicate the different compounds, with FG1181, EME and DNR marked as green, blue and red, respectively. The 
black arrows indicate the product noted as FG1181* in Figure 4.4. See respective figures for specification of well 
and pH- condition. Note that the values for the x-axes in A and B is lower than for C-F.  For details on the HPLC 




Figure 4.4 – Ability of compounds to cross phospholipid membranes. The bars represent the ratio of drugs 
present in the donor and acceptor wells of the PAMPA plate at different pH conditions in the acceptor and donor 
wells. The content of compounds was analyzed by RP-HPLC. A, B, and C represent the ratio of FG1181, Emetine 
(EME), and daunorubicin (DNR), respectively. The data presents the average of three experiments. For details on 




Figure 4.5 – Permeability of FG1181, emetine (EME) and daunorubicin (DNR) at different pH- conditions. 
The effective permeability Peff was calculated from RP-HPLC-quantification data applied to Equation 3.3 and 3.4, 
as described in chapter 3.4 in the Method section. Log(Peff)< -6.14 is defined as impermeable, -6.14 < log(Peff)< -
5.66 as low permeability, -5.66 < log(Peff)< -5.33 as intermediate permeability and log(Peff)over < -5.33 is 
considered as highly permeable (95). 
 
Introduction of a substituent on the secondary amine of EME is reported to yield an inactive 
molecule. It was therefore imperative to demonstrate cytotoxic effect of FG1181 to prove the 
prodrug concept. A dose response cell assays for FG1181 and EME as free drug was performed 
to compare the potency and the timescale of the cytotoxicity. EC50 and T50 are the values of the 
half maximal effective concentration and time, respectively, where half of all the cells appear 
dead. Figure 4.6 shows the measured metabolic activity after 24-hours incubation and images 
acquired with a fluorescence microscope to manually count the percentage of living versus 
dead cells. The non-apoptotic nuclei appear as evenly stained and bean-shaped (green arrows 
in Figure 4.6 C), whereas apoptotic nuclei are more brightly stained, and are fragmented (red 
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arrows). At very high concentrations of EME or FG1181, the cells appeared to have 
disintegrated and very few cells were present in the wells (Figure 4.6 D). Note that EME is 
more potent and kills the cells faster than FG1181. 
 
 
Figure 4.6 – Cytotoxicity of emetine and the analog FG1181 on MOLM13 AML cells. A, Dose-response 
curves comparing cell mortality after incubation for 24 hours and measuring of metabolic activity with the WST-
1-reagent. The curves are averages of the three experiments performed in triplicates and standard deviation.      B, 
Scheme showing a comparison of percentage apoptosis over time when treated with 2.5 µM FG1181 or 2.5 µM 
EME in a 24-hour kinetics assay described in chapter 3.5.3 in the Method section. Two images were acquired 
from each well, excluding images containing fewer than six cells. Each plot is an average of three experiments 
and standard deviation. The plots are adjusted for 30.49% cell death calculated from control. C and D, Images of 
untreated cells (C) and cells treated with FG1181 for 24 hours (D). Two examples of cells counted as apoptotic 
are marked with red arrows. Examples of cells counted as normal are marked with green arrows. Note that all the 





FG1181, EME and DNR, alone and in combinations, were tested on the non-malignant cell 
lines NRK and H9c2 (Figure 4.7). This was done to evaluate each compound’s cytotoxicity 
and estimate drug-related side-effects. The NRK cells appear to not be as affected as H9c2 by 
the treatment. A small beneficial effect for FG1181 compared to EME, alone and in 
combination with DNR, can be observed by the data.  
 
Figure 4.7 – Cytotoxicity of free drug on myocardium myoblast and kidney epithelial cells. 50 000 cells/mL 
were prepared in wells of a 96-well microplates 24 hours before free drug was added in concentrations given by 
the x-axis. The microplates were further incubated for 24 hours and metabolic activity evaluated using WST-1 
reagent as described in chapter 3.5.2 of the Method section. The data is an average of three experiments.  
 
4.2 Liposomal formulations 
Liposomes containing DNR and EME has been shown to efficiently kill AML cell lines (23). 
We wanted to improve this by adding a prodrug of EME for delayed protein synthesis 
inhibition. Liposomes containing DNR, FG1181 or EME, or DNR in combination with EME 
or FG1181 were therefore produced. Four batches (A-D) were produced, here batch B and C 
were extruded with a gas extruder, and batch A and D with a syringe-driven mini extruder. 
Batch A was produced before FG1181 was available. The loading of the batch was performed 
with 1:10 compound-lipid weight ratio. Batch B had a larger average size because of some 
technical trouble with the gas extruder. For Batch B-D the loading of FG1181 and EME was 
performed with 1:5 compound-lipid weight ratio. Batch C was produced to compare liposomes 
loaded using shaking and heat and liposomes loaded overnight in the refrigerator. Batch D was 
produced with folate (DSPE-PEG(5000)folate). Further specifications of loading conditions 
are given in Figure 4.9. 
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4.2.1 Liposomal characteristics 
The liposome sizes were measured in triplicates before and after loading to ensure that the 
liposomes were intact, and also had not agglomerated during drug loading or gel filtration 
(Figure 4.8). The PdI was < 0.078 for all measurements. The measured sizes and lipid content 
for the different batches are shown in Figure 4.9. The liposome sizes were measured in 
triplicates before and after loading to ensure that the liposomes were intact and had not 
agglomerated during compound loading or gel filtration. The lipid contents of the empty 
liposomes were calculated using Equation 3.1 after measurement with IR. For the liposomes 
containing DNR, a red band could be visibly detected as the loaded liposomes eluted from the 
SEC-column. The liposomes loaded with only EME or FG1181 were colorless, and to identify 
the liposomes, fractions were collected, and the lipid content measured. 
 
 
Figure 4.8 - Size distribution of empty liposomes after gel filtration. Size distribution measured with DLS. 




Figure 4.9 - Size and lipid content for the different liposome batches. Content of compounds and loading 
condition of the liposomes in the different batches are presented in the y-axes. The different batches are presented 
in different colors, as indicated. The blue indicates the batches produces with the mini-extruder and the green the 
batches produced with the gas-extruder. A, Lipid content measured with IR and calculated with Equation 3.1. B, 
Scheme of size measured with DLS for liposomes. The size is given as an average of three measurements of one 
sample after gel filtration. *The empty liposomes have a higher lipid content because they were only gel filtered 
once, compared to twice for the loaded liposomes. 
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4.2.2 Compound loading of liposomes 
The gradients were changed after Batch B showed that the peaks for DNR and FG1181 were 
very close and could not be separated using the mobile phase composition and gradient 
conditions presented in Figure 3.1 A. Figure 4.10 shows spectrums before and after gradient 
adjustment. The measured compound loading based on the RP-HPLC standard curves is 
presented in Figure 4.11. EME and DNR were loaded better with incubation at 60℃, while 
FG1181 was better loaded overnight at 4℃. DNR appear to hinder the uptake of EME and 
FG1181 when incubated at 60℃, as illustrated in Figure 4.11 A. 
 
Figure 4.10 – Examples of RP-HPLC-spectra of compounds from liposomes. Emetine (EME) is marked in 
blue, FG1181 in green and daunorubicin (DNR) in red. A, Analysis of a liposomal formulation containing FG1181 
and DNR from Batch B. The two peaks interject at t~5.60 minutes. Note the peak at t~4.20 minutes, indicating 
the presence of EME in the formulation. B, Example of a blank sample with gradient and background peaks at t 
~3.75, t~7.93 and t~11.41 minutes. These peaks were not evaluated in the measurements. C, Spectrum of a 
liposomal formulation containing FG1181 and DNR in Batch C. Note that the DNR and FG1181 peaks have base-




Figure 4.11 – Calculated compound loading for the liposomal formulations. The RP-HPLC standard curves 
were used to calculate compound loading. The x-axes specify batch and loading condition. A, Compound loading 
for FG1181 and EME liposomes. EME Batch A could not be quantified using RP-HPLC because of low 
compound content. B, Drug loading measured for the liposomes containing DNR. The loading of the combinations 
of FG1181 and DNR in Batch B is not given because of peak separation problems. The columns give the 
concentrations of DNR in the liposomal formulations. 
 
After producing some of the liposomal batches, we developed a hypothesis of FG1181 being 
degraded by high temperature. To investigate, the content of FG1181 and EME in equally 
prepared samples stored at different temperatures were compared. The compound was tested 
alone and in combination with DNR. The samples were analyzed using RP-HPLC to find the 
content of EME. Figure 4.12 shows RP-HPLC-spectrums obtained and the results from the 








Figure 4.12 – Content of EME in equally prepared samples stored at different temperatures. Samples 
containing free compound were either shaken at 60℃ for 60 minutes, illustrated in red, or stored dark at 4℃ 
overnight, illustrated in blue in E. The bars give the concentration of EME in samples with composition specified 
in the x-axis. The light- colored bars indicate where EME should be found, while the dark-colored bars are FG1181 
metabolized to EME. Note the difference between FG1181 alone and in combination with DNR. RP-HPLC was 
used to measure the contents in the samples. A-D, Spectrums of FG1181 alone treated with heat and cold, alone 
and in combination with DNR, respectively. EME is marked in blue, FG1181 in green and DNR in red. The 






All liposomal formulations were tested for cytotoxic potential towards MOLM13 cells. Dose 
response cell assays were performed to be able to compare EC50-values. Empty liposomes from 
all batches were tested for cytotoxic effect on MOLM13 cells as shown in Figure 4.13. Figure 
4.14 and 4.15 shows the cytotoxicity of free drug, as well as the different liposomal 
formulations and batches. Note the difference in EC50-values in Figure 4.14, indicating a 
synergistic effect of FG1181 and DNR compared to that of DNR alone or in combination with 
EME. For the liposomal formulations, this is especially clear for batch B and C where the 
FG1181-combination has EC50-values significantly lower than the EME-combination. The 
EC50-value for DNR as free drug is here 0.074 µM, while the value for a combination of DNR 
and FG1181 or EME is 0.002 µM, which is 37 times decrease in dosage.  
 
Figure 4.13 - Dose response cell assay with empty liposomes. Empty liposomes from every batch were tested 
on MOLM13 cells in three experiments. The scheme shows the average of Batches A-C and Batch D (folate). 
Twenty percent liposomal solution was added to the first well and diluted in a dose-response assay. The metabolic 
activity was measured after 24 hours of incubation utilizing WST-1 reagent. For details on cell assays, see chapters 
3.5.2 in the methods section. The data on PEGylated liposomes represent average and standard deviation of three 
separate experiments performed on three separate batches, while the data on folate decorated liposomes are the 





Figure 4.14 - Cytotoxicity of the different liposomal formulations and free compound combinations towards 
MOLM13 cells. All assays were performed in triplicates with standard deviation and incubated for 24 hours. The 
metabolic activity was measured with WST-1 reagent. Note that the plots are based on the concentration of DNR, 
not FG1181 or EME. See figure 4.11 A for concentration of FG1181 and EME in the different batches. A, Data 
from cell assays performed with DNR alone. B, Data from cell assays performed with a combination of DNR and 




Figure 4.15 - Cytotoxicity of the different liposomal formulations and free compound towards MOLM13 
cells. All assays were performed in triplicates with standard deviation and incubated for 24 hours. The metabolic 
activity was measured with WST-1 reagent. A, Data from cell assays performed with FG1181. B, Data from cell 
assays performed with EME. 
 
4.2.3 Pulse test 
A pulse test was performed with liposomes from Batch D (folate decorated liposomes). The 
test was performed because folate receptor targeting is most evident in short-term exposures 
and furthermore, we cannot assume that the liposomes are available for cellular uptake 
continuously for 24 hours (23). The results and experimental set ups are presented in Figure 
4.16. The assays indicated that a short incubation was sufficient to produce a strong cytotoxic 
effect on the AML-cells. It also showed decreasing metabolic activity for the 60 minutes assay 
compared to the 30 minutes assay for the cells treated with liposomes loaded with FG1181 or 
DNR, and for the samples treated as shown in Figure 4.16 B. Note the different concentrations 
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given by the y-axes, as the assay were performed with equal volume of liposomal solution 
added to the cells, and not adjusted to produce equal concentrations of compounds.  
 
 
Figure 4.16 – Pulse cytotoxicity test of compound loaded folate decorated liposomes on MOLM13-cells. 
After treatment, the cells were incubated for a total of 24 hours and metabolic activity measured with WST-1 
reagent. Note the difference in drug concentrations for the liposomes specified in the x-axes as the assays were 
performed with the same percentage of liposomal formulation, not compound concentration. A and B, Schematic 
presentation of the timelines of the assay. From the wash-step, the cells were spinned down and resuspended in 
fresh medium. C and D, Results from the 30 minutes and 60 minutes tests, respectively. The data are an average 




In this study, we evaluated the emetine (EME) analog FG1181 as a combination therapy with 
daunorubicin (DNR) against AML. The synergism with DNR and the novel analog FG1181 
was compared to that of DNR and EME. Furthermore, successful loading of liposomes with 
FG1181 was achieved both alone and together with DNR. The efficacy of the compound loaded 
liposomes was demonstrated on the AML cell line MOLM13 and finally, we demonstrated that 
FG1181 and DNR were superior on MOLM13 AML cells compared to EME and DNR. 
In silico predictions showed the protonation of the primary amine for FG1181 (Figure 4.1). 
However, after metabolization to EME, the compound can be further protonated on EME’s 
secondary amine (green circle, figure 4.1 A). The peak apparent in the RP-HPLC spectra in 
Figure 4.3 at t~5:30-6:20 minutes can be hypothesized to degradation products of the two 
compounds. The RP-HPLC spectra in Figure 4.10 showed several gradient and background 
peaks which might have affected the readings, especially for EME at t~4.20 minutes, but not 
the noted peak. The large gradient peak at t~3.75 minutes in all spectra caused by the 
acetonitrile can be assumed to have influenced the readings to some degree, even though it was 
present at the standard curve, because it differs some in value and thereby impact the result. 
This would not be a problem if the concentration of EME was higher, as the peaks then would 
be larger and less affected. It must also be noted that using an autosampler would lead to more 
equal injections.  
The different assays performed illustrates that there are differences between EME and FG1181 
in terms of ionization, lipophilicity, membrane permeability, cytotoxicity and stability as 
illustrated in Figures 4.1, 4.5-4.7 and 4.13-4.16. PAMPA presented in Figures 4.3-4.5 was 
performed to estimate whether FG1181, EME and DNR cross the liposomal barrier passively. 
The different pH conditions affected all three compounds, but particularly FG1181. The 
acceptor wells with pH 6.4 contained between 70 and 80% of the FG1181 (Figure 4.4), and the 
calculated log(Peff)-values were -4.25 and -4.30, alone and in combination with DNR (Figure 
4.5). These values show that the compound has high ability to cross membranes at the pH 
conditions where the majority of the compound is uncharged (Figure 4.1 and 4.5).  
Furthermore, the accumulation of FG1181 in the acceptor well suggest that the compound is 
trapped here presumably because the low pH protonates the primary amine (Figure 4.1). Both 
DNR and EME went from having low permeability to intermediate permeability when 
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comparing pH values of 7.4 to that of 8.0 in the donor and 6.4 in the acceptor wells (Figure 
4.5). Although not as dramatic as for FG1181, there was a notable higher drug content in the 
acceptor wells corresponding to the increase in permeability.  
For the PAMPA it must be noted that the membrane, unlike liposomes and cells, does not 
contain cholesterol. Cholesterol highly affects the stability and permeability of a membrane. 
This study shows, with the liposomal formulations that DNR and EME do cross the liposomal 
barrier given the same pH conditions as in the assay (PBS pH 8.0 and ammonium sulphate pH 
6.4). This highlights the fact that a pre-made PAMPA can only be used as an indicator for 
membrane permeability. Furthermore, the PAMPA was performed at room temperature, which 
did not exceed the membrane’s transition temperature. Still, we noted that with the same pH 
gradient as in the liposomes, there was an increase in permeability from -5.86 to -5.67 
(log(Peff)-values) for DNR alone (Figure 4.5) and an increase in the content in the acceptor well 
of 38% (Figure 4.4).  
The dose response and kinetics curves shown in Figure 4.6 compare the cytotoxic potential of 
FG1181 and EME as free compounds. They show that EME has lower EC50 and T50, compared 
to FG1181. Both compounds reach complete cell death at the same concentration (2.5 µM) 
after 24 hours (Figure 4.6 A). The difference in EC50-values could be explained by FG1181 
being less potent than EME. It can also be caused by the desired prodrug effect, meaning that 
it was degraded to the active compound EME after a certain time period. This was supported 
by the kinetics assay showing that the T50-value of FG1181 appeared approximately 150 
minutes after that of EME. In the assay, FG1181 used approximately 18 hours to reach 
complete cell death compared to 12 hours for EME. This might be caused by FG1181 being 
more lipophilic than EME, leading to the possibility of it binding to lipophilic binding site in 
plasma protein or lipoprotein and being less available for uptake in cells. Incorporating FG1181 
in liposomes will protect the compound from these bindings, thereby leading to a higher uptake 
of the compound into the cells. For the free compound in Figure 4.15, a higher EC50-value is 
observed compared to the liposomal formulations, but this might be caused by degradation to 
a more active EME. However, to fully establish that FG1181 is inactive and converted to active 
EME either in medium or intracellularly, liquid chromatography-mass spectroscopy (LC-MS) 
analyses of the compounds from cell lysates could be made. It must be noted that the control 
well in the time kinetics assay has an unusual high level of cell death. However, as the assay 
was performed using microscopy, the exact cell count of each well is not relevant.  
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FG1181 showed lower toxicity towards non-malignant cell lines compared with EME, both 
alone and in combination with DNR (Figure 4.7). This can be interpreted as an FG1181 being 
less cytotoxic for these cell lines and thereby will lead to less drug-related side-effects, for 
instance cardiomyopathy. DNR shows less toxicity for the H9c2 cell line alone at the given 
dose. However, the color of DNR interferes with the assay and high DNR concentrations might 
give positive results for metabolic activity, but for comparing DNR alone or in combination 
with a protein synthesis inhibitor, the color effect of DNR is expected to be equal. A decrease 
in side-effects would improve the treatment of AML, especially for frailer patients that do not 
tolerate the current treatment methods.  
Different conditions for liposomal production and drug loading were tested to find which 
method gave the optimal result with respect to size distribution and compound loading. The 
size distribution between the batches varied little, being between 113.7 nm and 140.4 nm 
(Figure 4.8 and Figure 4.9), which correlates well with clinical recommendations (53). Batch 
B, produced with the gas extrusion, gave the largest liposomes with the highest measured lipid 
content after the second gel filtering probably due to a faulty filter. The liposomal formulations 
with a combination of EME/FG1181 and DNR were shown to be larger than single compound 
loaded liposomes in average (Figure 4.9). 
RP-HPLC of the liposomal batches showed that more EME was loaded into the liposomes 
using incubation at 60℃, compared to diffusion overnight in the dark at 4℃ (Figure 4.11). 
This correlates well with the data from the PAMPA plate (Figures 4.4 and 4.5), which showed 
that FG1181 diffused over the membrane passively to a greater extent than EME. Both EME 
and DNR showed a higher degree of loading at temperatures exceeding the phase transition 
temperature of the lipid membrane (Figure 4.11). However, loading of both FG1181 and DNR 
proved difficult because of difference in optimal loading conditions. Studies showed that 
FG1181 seemed to be degraded to EME at high temperatures (≥ 60℃). The PAMPA was 
performed at room temperature and the loading at ≥ 60℃, which might have affected FG1181 
as further temperature studies (Figure 4.12) showed that the compound is highly affected by 
increased temperature (≥ 60℃). When comparing the FG1181 samples illustrated in Figure 
4.12, it became apparent that more EME was present in the sample incubated at 60℃ for one 
hour compared to the samples incubated at 4℃ overnight. For the heat-treated sample 
containing a combination of FG1181 and DNR, no FG1181 was detected compared to 0.2 µM 
for the sample stored in the dark at 4℃, suggesting that the presence of DNR facilitated 
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degradation of FG1181. It was also shown that more FG1181 was metabolized in the presence 
of DNR compared to alone (Figure 4.12).  
A compound´s lack of tolerance to temperature change can greatly affect its clinical use. As 
FG1181 has here been shown to be less stable at increased temperatures (≥ 60℃), but with 
unknown response to room temperature, the handling of a potential drug formulation before 
administrations needs to be done with extra care. Some cytostatics are prepared and heated 
before infusion to avoid discomfort for the patient, but in this case FG1181 would have to be 
prepared, stored and infused cold, perhaps as a freeze dried powder. The cytostatic Bortezomib 
is an example of an infusion in clinical use that needs to be administered no more than eight 
hours after reconstitution because it is unstable at room temperature (109). However, it must 
be emphasized that the purpose of this study was to develop a suggestion for improved 
treatment of AML, not to produce a standard operating procedure to produce a specific drug. 
The study was not performed at a pharmaceutical production facility, and some expected batch 
variations were observed.    
In Figure 4.11, “DNR+FG1181” was loaded overnight in the dark at 4℃ for Batch C (cold) 
and Batch D (folate decorated liposomes). These show a lower drug concentration than the 
batches loaded by incubation at 60℃. It must be noted that “EME+DNR” and DNR were 
loaded by heat incubation at 60℃ in Batch D, and therefore have a higher DNR concentration 
compared to “FG1181+DNR” which was loaded in the dark at 4℃. In the future, one might try 
to load the liposomes with DNR at 60℃ first, then cool the liposomal formulation down, before 
adding FG1181 in the dark overnight at 4℃. This might improve the loading. On the other 
hand, DNR seem to obstruct the uptake of EME and FG1181 when loaded at 60℃, which 
might indicate that this sequncial loading might not improve the uptake of compound (Figure 
4.16). 
An attempt of first loading liposomes with FG1181/EME for 30 minutes and then add DNR 
produced liposomes which were cytotoxic, but quantification by RP-HPLC was not successful 
for the FG1181 batch due to the lack of baseline separation of peaks (Figure in Appendix II). 
The liposomes first loaded with EME and then DNR did not show any improved loading for 
EME. The hypothesis was that by incorporating FG1181 into the liposomes first, the compound 
would be protected from degradation by DNR and ensure a higher uptake. The RP-HPLC 
spectrum (Appendix II) showed little EME in this sample compared to that found in Figure 
4.13 A where DNR and FG1181 were loaded together. This indicates that the liposomes protect 
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the FG1181 from being degraded by DNR and correlates well with the data from the PAMPA 
plate (Figure 4.4), which showed no EME in the FG1181 acceptor wells with pH 6.4, which 
can be compared to the interior of the liposomes.   
The liposomes loaded with DNR at 60℃ showed less variation in drug compared to liposomes 
loaded with EME and FG1181 alone. This can be partly explained by the liposomes loaded 
with DNR being colored red, thereby making them easier to detect during gel filtration. This 
became apparent for the folate decorated liposomes which had lower loading of FG1181 and 
EME compared to the PEGylated liposomes (Figure 4.11). The folate might have interfered 
with the compound loading, or the fractionation of liposomes loaded with the clear compounds 
might have been unsuccessful. The same column was used for all gel filtrations and was 
thoroughly rinsed between every filtration, but it would be optimal to have separate columns 
for each formulation to ensure that no compound was transferred. In many cases, targeted 
nanocarriers are added to the targeting ligand after production. It is therefore possible to first 
load the liposomes with drugs, and then add the targeting moieties, either small molecules or 
antibodies (110). This will prevent that surface molecules reduce loading efficiency. For the 
liposomal formulation created overnight at 4℃, Batch D (folate decorated liposome), the EC50-
value of FG1181 was lower than that of EME, contrary to what was seen with non-folate 
liposomes (Figure 4.15). One explanation for this can be that FG1181 was degraded to EME 
during preparation of the liposomes, and that EME is the main constituent of these liposomes.  
When comparing the results from DNR alone and in combination with a protein synthesis 
inhibitor, the combination appears favorable (Figure 4.14), which correlates well with earlier 
data (23, 47, 57). For free drug, EC50-values were 0.07 µM for DNR alone and 0.002 µM for 
DNR in combination with EME or FG1181 of different concentrations. Overall, FG1181 shows 
promising results for synergistic use with DNR. The EC50-values for the folate covered 
liposomes was almost twenty-fold higher for DNR alone compared to the combination of both 
FG1181 and EME (Figure 4.14). Both the batch incubated at 60℃ and the batch incubated at 
4℃ favors FG1181 (Figure 4.14 B and C). 
The pulse test was performed because in the circulating blood or in the bone marrow, the 
AML blasts might not be exposed to the liposomes continuously for 24 hours as is the case 
with our cell experiments. In order to mimic a shorter exposure time, we exposed the 
MOLM13 cells to the liposomes for a short pulse of 30 or 60 minutes, followed by wash 
and further incubation in a drug free medium for another 23 hours (Figure 4.16).  Increased 
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cytotoxicity was observed for the 60-minutes assay compared to the 30-minutes assay, but 
the assays both had substantial standard deviation. However, earlier research has shown that 
a short exposure period of liposomes is enough to ensure effect (111). As shown in Figure 
4.14, the same concentration of DNR in the folate decorated liposomes gave a metabolic 
activity of 0.18 relative to control, while it in the pulse test in Figure 4.16 gives values of 
0.63 and 0.48 for the 30- and 60-minutes assay, respectively. Liposomes containing both 
FG1181 and DNR did not show an increase in cell death compared to liposomes with DNR in 
Figure 4.16, but the low concentration of DNR in the combination liposomes must be noted. 
For future investigations, the test should be performed with the same compound concentration 
instead of identical liposomal concentrations.  
We also wanted to investigate whether FG1181 and EME had equal effects on cellular 
signaling, and studied cleavage of Caspase 3, an indication of apoptosis with Western blot. 










6 Concluding remarks and further investigations 
The aims of this master thesis were to investigate the biological activity of FG1181 and 
compare it to that of emetine (EME), incorporate it in liposomes and investigate synergism 
with daunorubicin (DNR). The combination of DNR and FG1181 appears to be beneficial for 
the patient, both as free drug and incorporated into liposomes. FG1181 was showed to have a 
time delayed cytotoxicity compared to EME, but its temperature instability can pose a problem 
in the production and handling of the liposomal formulation. Small molecules, here liposomes, 
show promising results in the field of cancer therapy and could be expected to decrease drug-
related side-effects. 
For further investigations, other analogs of EME could be developed to see if more heat-stable 
molecules could be produced. A more heat stable analog with prodrug effect would be easier 
to handle in the production and for administration of the liposomal formulation. It would also 
be easier to obtain sufficient and reliable loading of the liposomes with both DNR and an EME 
analog if the temperature could exceed the phase transition temperature of the liposomal 
membranes. Further temperature studies of the FG1181 could have been performed, for 
instance by loading the compound into liposomes at room temperature and at other 
temperatures to investigate if this led to a higher degree of compound loading. 
For future investigations, we would have liked to perform the pulse test with the same 
concentration of compound and in a dose-response assay with decreasing concentrations. It 
would be interesting to test liposomal formulations on the non-malignant cell lines and do a 
kinetics assay with liposomal FG1181 to compare with the results found for free drug. The 
kinetics assay could also have been repeated with the compounds’ EC50-concentrations. We 
would have liked to investigate and compare more ways to load FG1181 into liposomes, for 
instance by first loading FG1181 into the liposomes in the dark at 4℃ overnight and then load 
DNR at 60℃ for one hour, or vice versa with cooling the formulation to 4℃ before adding 
FG1181. LS-MS could be used to establish whether FG1181 is in fact an inactive compound 
being converted into a more active EME.  
Finally, the documentation provide in this thesis for a prodrug of EME for delayed activity is 
sufficient to pursue the concept in animal models of AML. If efficacy can be demonstrated in 
for instance a mouse AML xenograft model, it could very well be that the pharmaceutical 
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Appendix I - Western blotting results 
 
Figure App.I – Bradford assay for calculation of protein concentration in the lysates. A, The standard curve 
used to calculate protein concentration in the lysates. B, Protein concentration in the lysates used for Western 
blotting. Note that blotting was performed with two concentrations of FG1181. 
 
Figure App. II – Western blotting images: Images of bonds on the membrane. The bonds are placed in the  
same order as the column in App.I.. A, Image after Ponceau staining of the membrane. B, Caspase 3.C, β-actin. 
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Appendix II – RP-HPLC spectra of FG1181 and daunorubicin loaded liposomes 
 
Figure App. III – RP-HPLC spectrum of FG1181 and Daunorubicin loaded liposomes form Batch B. The 
liposomes were loaded first with FG1181 for 30 minutes at 60℃ and then DNR was added. Note the low emetine 
top marked with the blue arrow. The green and red arrow indicate FG1181 and DNR without base peak separation.  
